Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Biomarkers as new tools to improve the diagnosis and treatment of PTSD (CROSBI ID 50465)

Prilog u knjizi | izvorni znanstveni rad

Pivac, Nela ; Nedić, Gordana ; Kozarić-Kovačić, Dragica ; Nikolac, Matea ; Grubišić-Ilić, Mirjana ; Mustapić, Maja ; Jendričko, Tihana ; Rakoš, Iva ; Muck-Šeler, Dorotea Biomarkers as new tools to improve the diagnosis and treatment of PTSD // New tools to enhance posttraumatic stress disorder diagnosis and treatment : invisible wounds of war / Wiederhold, Brenda K. (ur.). Amsterdam: IOS Press, 2013. str. 21-74

Podaci o odgovornosti

Pivac, Nela ; Nedić, Gordana ; Kozarić-Kovačić, Dragica ; Nikolac, Matea ; Grubišić-Ilić, Mirjana ; Mustapić, Maja ; Jendričko, Tihana ; Rakoš, Iva ; Muck-Šeler, Dorotea

engleski

Biomarkers as new tools to improve the diagnosis and treatment of PTSD

PTSD is a serious and debilitating psychiatric disorder that can develop in individuals who were exposed to one or more intense traumatic event(s). Since not all people exposed to traumatic experience develop PTSD, it is assumed that different neurobiological, genetic and environmental risk factors are involved in the vulnerability and/or resilience to PTSD. PTSD biomarkers, defined as characteristics that objectively measure and evaluate normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention, might improve the diagnosis and treatment of PTSD. Determined biomarkers were peripheral biochemical markers such as platelet serotonin (5-HT) concentration, platelet monoamine oxidase type B (MAO-B) activity, plasma dopamine-beta-hydroxylase (DBH) activity, and genetic markers /MAO-B intron 13, -1021C/T DBH, catechol-o-methyltransferase (COMT) val158/108met, brain-derived neurotrophic factor (BDNF) val66met, 102T/C serotonin receptor type 2A gene (5HT2A) polymorphism and serotonin transporter (5HTT) gene-linked polymorphic region (5HTTLPR)/. Study participants were Croatian male war veterans with or without current and chronic combat-related PTSD, recruited from the Referral Centre for the Stress-related Disorders of the University Hospital Dubrava, Zagreb. Only plasma DBH activity, but not other markers, differed significantly between war veterans with or without PTSD. When veterans were subdivided according to the narrow clinical symptoms (such as psychotic features, sleep disturbances, suicidal behavior), platelet 5-HT concentration, platelet MAO-B activity, and val66met BDNF were significantly different among these groups. The results indicate that specific PTSD biomarkers, associated with the narrow clinical features, might be indicators of PTSD traits, state or progression, and might be used to improve the diagnosis and treatment of PTSD.

PTSD, war veterans, biochemical markers, genes, narrow clinical features, polymorphisms, risk factors

ISSN 1874-6276

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

21-74.

objavljeno

Podaci o knjizi

New tools to enhance posttraumatic stress disorder diagnosis and treatment : invisible wounds of war

Wiederhold, Brenda K.

Amsterdam: IOS Press

2013.

978-1-61499-188-5

Povezanost rada

Temeljne medicinske znanosti